Yassen Ashraf, Olofsen Erik, Kan Jingmin, Dahan Albert, Danhof Meindert
Leiden/Amsterdam Center for Drug Research, Division of Pharmacology, Gorleaus Laboratories, Leiden, The Netherlands.
Clin Pharmacokinet. 2007;46(5):433-47. doi: 10.2165/00003088-200746050-00005.
This investigation describes the interspecies scaling of the pharmacokinetics and pharmacodynamics of buprenorphine.
Data on the time course of the antinociceptive and respiratory depressant effects of buprenorphine in rats and in humans were simultaneously analysed on the basis of a mechanism-based pharmacokinetic-pharmacodynamic model.
An allometric three-compartment pharmacokinetic model described the time course of the concentration in plasma. The value of the allometric coefficient for clearance was 35.2 mL/min (relative standard error [RSE] = 5.6%) and the value of the allometric exponent was 0.76 (RSE 5.61%). A combined biophase distribution-receptor association/dissociation model with a linear transduction function described hysteresis between plasma concentration and effect. The values of the drug-specific pharmacodynamic parameters were identical in rats and in humans. For the respiratory depressant effect, the values of the second-order rate constant of receptor association (k(on)) and the first-order rate constant of receptor dissociation (k(off)) were 0.23 mL/ng/min (RSE = 15.8%) and 0.014 min(-1) (RSE = 27.7%), respectively, and the value of the equilibrium dissociation constant (K(diss)) was 0.13 nmol/L. The value of the intrinsic activity alpha was 0.52 (RSE = 3.4%). For the antinociceptive effect, the values of the k(on) and k(off) were 0.015 mL/ng/min (RSE = 18.3%) and 0.053 min(-1) (RSE = 23.1%), respectively. The value of the K(diss) was 7.5 nmol/L. An allometric equation described the scaling of the system-specific parameter, the first-order distribution rate constant (k(e0)). The value of the allometric coefficient for the k(e0) was 0.0303 min(-1) (RSE = 11.3%) and the value of the exponent was -0.28 (RSE = 9.6%).
The different values of the drug-specific pharmacodynamic parameters are consistent with the different opioid mu receptor subtypes involved in the antinociceptive and respiratory depressant effects.
本研究描述了丁丙诺啡药代动力学和药效学的种间缩放。
基于一种基于机制的药代动力学-药效学模型,同时分析了丁丙诺啡在大鼠和人类体内的抗伤害感受和呼吸抑制作用的时间进程数据。
一个异速三室药代动力学模型描述了血浆中浓度的时间进程。清除率的异速系数值为35.2 mL/min(相对标准误差[RSE]=5.6%),异速指数值为0.76(RSE 5.61%)。一个具有线性转导函数的联合生物相分布-受体结合/解离模型描述了血浆浓度与效应之间的滞后现象。药物特异性药效学参数在大鼠和人类中的值相同。对于呼吸抑制作用,受体结合的二级速率常数(k(on))和受体解离的一级速率常数(k(off))的值分别为0.23 mL/ng/min(RSE = 15.8%)和0.014 min(-1)(RSE = 27.7%),平衡解离常数(K(diss))的值为0.13 nmol/L。内在活性α的值为0.52(RSE = 3.4%)。对于抗伤害感受作用,k(on)和k(off)的值分别为0.015 mL/ng/min(RSE = 18.3%)和0.053 min(-1)(RSE = 23.1%)。K(diss)的值为7.5 nmol/L。一个异速方程描述了系统特异性参数一级分布速率常数(k(e0))的缩放。k(e0)的异速系数值为0.0303 min(-1)(RSE = 11.3%),指数值为-0.28(RSE = 9.6%)。
药物特异性药效学参数的不同值与抗伤害感受和呼吸抑制作用中涉及的不同阿片μ受体亚型一致。